|
|
|
|
|
Product Name
|
ADAM12 peptide (Aminoterminal end)
|
|
Product type
|
Proteins and Peptides
|
|
Peptide
|
This peptide was used as an immunogen for ab39155 - ADAM12 antibody - Aminoterminal end.
|
|
Specificity
|
We have a range of domain specific antibodies for this target. For a full list please see all ADAM12 antibodies
|
|
Tested applications
(see key)
|
WB
|
|
Application notes
(see key)
|
Recommended dilutions
WB: Use at an assay dependent dilution.
This peptide can be used with studies using ab39155. Dilution optimised using Chromogenic detection.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
|
|
Research areas
|
Cell Biology >> Proteolysis / Ubiquitin >> Proteolytic enzymes >> Metalloprotease >> ADAMs
Cancer >> Invasion/microenvironment >> ECM >> Extracellular matrix >> ADAM protein family
Signal Transduction >> Cytoskeleton / ECM >> Extracellular Matrix >> ECM Enzymes >> ADAM Protein Family
Signal Transduction >> Cytoskeleton / ECM >> Cell Adhesion >> Integrins >> Beta
Signal Transduction >> Cytoskeleton / ECM >> Cell Adhesion >> Integrins >> Alpha
|
|
Relevance
|
ADAM12 is a member of the ADAM (a disintegrin and metalloprotease like domain) family. Two forms of ADAM12 have been described: ADAM12S and ADAM12L (short and long forms). The short form is a soluble form lacking the transmembrane and cytoplasmic domains. The short form of ADAM12 was reported to provoke myogenesis, and the lack of cytoplasmic domain suggests different regulation pathways (although both forms can be expressed in the same tissue). Other papers investigated the SH3 ligand domains in the cytoplasmic portion of ADAM12, demonstrating regulation routes for ADAM12 via Src and Src tyrosine kinase. ADAM12 is primarily expressed in muscle and bone (although placenta, osteoblasts, and many tumor cell lines also express ADAM12). ADAM12 supports cell adhesion by acting as a cell attachment molecule and binding integrins through the cysteine rich domain. A marker of skeletal muscle regeneration, it has been implicated in myoblast differentiation and fusion. ADAM12 contains the canonical HExxHxxxxxH zinc metalloproteinase motif. Full length ADAM12 (909 amino acids) has a predicted mass of 99.5 kDa, but due to glycosylation and cyteine rich regions, the reduced protein migrates to 114 kDa (unprocessed) and 84 kDa (processed). The soluble form of ADAM12 (738 amino acids, predicted mass of 80.5 kDa) is seen as a 92 kDa zymogen and 68 kDa furin processed form.
|
|
|
|
|
Purity
|
>95% by SDS-PAGE
|
|
Storage buffer
|
Preservative: None
Constituents: 0.001% Tween 20, 30mM HEPES, 2mM EDTA, 150mM Sodium chloride, pH 6.75
|
|
Form
|
Liquid
|
|
Concentration
|
1.000 mg/ml
|
|
Storage instructions
|
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
|
| |
At Abcam, we have one centralized database to hold all of our product information, so that everything we know about this ADAM12 peptide (Aminoterminal end) is on this datasheet. But please do contact us if you would like any reassurance! |
 |
|
| |
|
Search PubMed (MEDLINE) for references to ADAM12
|
| |
ADAM12 peptide (Aminoterminal end) - more information
|
Customer reviews (feedback) regarding ADAM12 peptide (Aminoterminal end) |
Customer FAQs regarding ADAM12 peptide (Aminoterminal end) |
Protocols for ADAM12 peptide (Aminoterminal end) |
Price and availability of products related to ADAM12 peptide (Aminoterminal end) |
| |
ADAM12 peptide (Aminoterminal end) - related products:
|
|
|
| |
ADAM12 peptide (Aminoterminal end) - other tools:
|
Contact Abcam with a Technical Enquiry about ADAM12 peptide (Aminoterminal end) |
| |
All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"
Pricing information loading
